Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426009361?dgcid=rss_sd_all
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426009361?dgcid=rss_sd_all
“Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.” Annals of Oncology.
@article{article88398,
title = {Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426009361?dgcid=rss_sd_all}
}
ABSTRACT Diagnosing and classifying platelet disorders (PD) is challenging in children. Therefore, we evaluated clinical, laboratory, and genetic data to improve current algorithms by performing a prospective observational cohort study...
Abstract Background and Objectives Perioperative blood transfusion in hip arthroplasty is associated with increased morbidity, prolonged hospitalization, and higher costs. This study aimed to identify independent risk factors and...